| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $1,955,000 | 2024 | THE CUREALZ ALZHEIMER'S GENOME PROJECT |
| BRIGHAM AND WOMEN'S HOSPITAL | BOSTON, MA | $431,250 | 2024 | A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $345,000 | 2024 | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE |
| NORTHWESTERN UNIVERSITY | CHICAGO, IL | $345,000 | 2024 | MBC: INTERACTION OF THE MICROBIOME WITH ASTROCYTES AND AMYLOID PATHOLOGY |
| WASHINGTON UNIVERSITY | ST LOUIS, MO | $345,000 | 2024 | BEE: CROSSTALK OF CNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND ALZHEIMER'S DISEASE |
| WASHINGTON UNIVERSITY | ST LOUIS, MO | $345,000 | 2024 | APOE CONSORTIUM: ROLE OF APOE ISOFORMS IN IMMUNE RESPONSES IN A MODEL OF TAUOPATHY |
| BOSTON CHILDREN'S HOSPITAL | BOSTON, MA | $344,085 | 2024 | NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE |
| UNIVERSITY OF SOUTHERN CALIFORNIA | LOS ANGELES, CA | $301,069 | 2024 | AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $300,000 | 2024 | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | CAMBRIDGE, MA | $300,000 | 2024 | CIRCUITS: DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE |
| BRIGHAM AND WOMEN'S HOSPITAL | BOSTON, MA | $287,500 | 2024 | MBC: HARNESSING DIET-MICROBE INTERACTIONS TO PREVENT ALZHEIMER'S DISEASE PATHOGENESIS |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | LA JOLLA, CA | $287,500 | 2024 | NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION |
| BOSTON UNIVERSITY | BOSTON, MA | $287,500 | 2024 | APOE CONSORTIUM: MODULATION OF SELECTIVE NEURONAL VULNERABILITY IN ALZHEIMER'S DISEASE BY APOE |
| WASHINGTON UNIVERSITY | ST LOUIS, MO | $287,500 | 2024 | MBC: THE ROLE OF GUT MICROBIAL METABOLISM IN TAU-MEDIATED NEURODEGENERATION |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $287,500 | 2024 | MBC: MICROBIAL PROFILING OF HUMAN BRAIN AND GUT MICROBIOMES IN ALZHEIMER'S DISEASE |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | LA JOLLA, CA | $287,500 | 2024 | BEE: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMER'S DISEASE |
| WEILL CORNELL | NEW YORK, NY | $287,500 | 2024 | BEE: BIOCHEMICAL AND FUNCTIONAL ANALYSIS OF CSF AND LYMPH FOLLOWING CHANGES IN BRAIN FLUID DYNAMICS |
| BRIGHAM AND WOMEN'S HOSPITAL | BOSTON, MA | $287,500 | 2024 | APOE CONSORTIUM: APOE4-MEDIATED DYSFUNCTION OF CD8 T CELL-MICROGLIA CROSSTALK IN ALZHEIMER'S DISEASE |
| UNIVERSITY OF CALIFORNIA IRVINE | IRVINE, CA | $287,493 | 2024 | NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $287,169 | 2024 | ADTC: HOW DO SOLUBLE TAU SPECIES REPLICATE? |
| UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | DALLAS, TX | $287,000 | 2024 | ADTC: ROLE OF VCP/P97 IN TAU PRION REPLICATION |
| NORTHWESTERN UNIVERSITY | CHICAGO, IL | $286,448 | 2024 | ADTC: THE ROLE OF A-INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $258,750 | 2024 | FUNCTIONAL CHANGES TO CEREBROSPINAL FLUID IMMUNE CELLS RESULTING FROM BACILLUS CALMETTE-GURIN (BCG) VACCINATION IN OLDER ADULTS WITH AND WITHOUT ALZHEIMER'S DISEASE |
| UNIVERSITY OF CHICAGO | CHICAGO, IL | $250,000 | 2024 | MBC: TEMPORAL RELATIONSHIPS BETWEEN GUT DYSBIOSIS, BRAIN AB METABOLISM AND MICROGLIA CELL ACTIVATION FOLLOWING ANTIBIOTIC TREATMENT |
| WEILL CORNELL | NEW YORK, NY | $250,000 | 2024 | DEVELOPMENT OF HUMAN CGAS INHIBITORS TO TREAT ALZHEIMER'S DISEASE |
| UNIVERSITY OF SOUTHERN CALIFORNIA | LOS ANGELES, CA | $250,000 | 2024 | CELLULAR AND MOLECULAR STUDIES OF APOE REGULATION OF BLOOD-BRAIN BARRIER, SYNAPTIC AND NEURONAL FUNCTIONS AND PROTECTION STRATEGIES IN MOUSE MODELS WITH AND WITHOUT ALZHEIMER'S PAHTOLOGY |
| UNIVERSITY OF SOUTHERN CALIFORNIA | LOS ANGELES, CA | $234,709 | 2024 | PROTECTION AGAINST APOE4 WITH LONGEVITY-PROMOTING INTERVENTIONS |
| UNIVERSITY OF CALIFORNIA IRVINE | IRVINE, CA | $230,000 | 2024 | ENDOGENOUS HUMAN ANTIBODIES ASSOCIATED WITH ALZHEIMER'S DISEASE |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $230,000 | 2024 | BEE: A 3D IN-VITRO NEURO-VASCULAR HUMAN BRAIN MODEL WITH MENINGEAL LYMPHATICS FOR ELUCIDATING MECHANISMS UNDERLYING ALZHEIMER'S DISEASE |
| UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | DALLAS, TX | $230,000 | 2024 | RNA AS A DETERMINANT OF TAU SEEDING |
| UNIVERSITY OF CONNECTICUT | FARMINGTON, CT | $230,000 | 2024 | AD PATHOPHYSIOLOGY ALTERS THE LEVEL OF ELECTRICAL AND CHEMICAL SYNAPSE COUPLING IN THE NETWORK OF GABAERGIC PV+ INTERNEURONS EARLY IN DISEASE COURSE |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | LA JOLLA, CA | $230,000 | 2024 | APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER'S DISEASE IN DOWN SYNDROME |
| MEMORIAL SLOAN KETTERING CANCER CENTER | NEW YORK, NY | $230,000 | 2024 | THE ROLE OF IFITM3 AND Y-SECRETASE IN MICROGLIA |
| DUKE UNIVERSITY SCHOOL OF MEDICINE | DURHAM, NC | $229,994 | 2024 | UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES |
| HARVARD MEDICAL SCHOOL | CAMBRIDGE, MA | $220,071 | 2024 | ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE |
| NEW YORK UNIVERSITY | NEW YORK, NY | $208,033 | 2024 | MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE |
| YALE UNIVERSITY | NEW HAVEN, CT | $204,081 | 2024 | BEE: CNS FLUID HOMEOSTASIS AND WASTE CLEARANCE IN ALZHEIMER'S DISEASE CHARACTERIZED BY MRI |
| COLUMBIA UNIVERSITY | NEW YORK, NY | $201,501 | 2024 | NEUROPROTEASOMES MECHANISTICALLY CONNECT APOE ISOFORMS TO ENDOGENOUS TAU AGGREGATION |
| UNIVERSITY OF MICHIGAN | ANN ARBOR, MI | $201,250 | 2024 | MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD |
| THE SALK INSTITUTE FOR BIOLOGIAL STUDIES | LA JOLLA, CA | $201,250 | 2024 | TO ELUCIDATE THE ROLE OF MEMORY T CELLS AS A DETERMINANT OF AGE-RELATED INFLAMMATION IN ALZHEIMER'S DISEASE |
| BRIGHAM AND WOMEN'S HOSPITAL | BOSTON, MA | $201,250 | 2024 | TARGETING NEUROINFLAMMATION WITH NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO TREAT ALZHEIMER'S DISEASE |
| ICAHN SCOOL OF MEDICINE AT MOUNT SINAI | NEW YORK, NY | $201,250 | 2024 | INVESTIGATING MEF2C TRANSCRIPTION FACTOR AS THERAPEUTIC TARGET TO REPROGRAM PATHOLOGICAL MICROGLIAL STATES IN ALZHEIMER'S DISEASE |
| JOHNS HOPKINS UNIVERSITY | BALTIMORE, MD | $201,250 | 2024 | HUMAN BRAIN CD33 LIGAND, RPTPS3L, LIMITS MICROGLIAL PHAGOCYTOSIS AND CONTRIBUTES TO ALZHEIMER'S DISEASE PROGRESSION |
| COLUMBIA UNIVERSITY | NEW YORK, NY | $201,250 | 2024 | NONCODING TRANSLATION FEEDBACK LOOP IN ALZHEIMER'S DISEASE |
| STANFORD UNIVERSITY | REDWOOD CITY, CA | $201,250 | 2024 | MULTIOMICS CHARACTERIZATION OF TAU PATHOLOGY ONSET AND ITS RELATIONSHIP WITH AMYLOID IN THE HUMAN HIPPOCAMPUS |
| WEILL CORNELL | NEW YORK, NY | $201,250 | 2024 | IDENTIFICATION AND DEVELOPMENT OF CD33 INHIBITORS AND PRE-RNA SPLICING MODULATORS |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $201,250 | 2024 | ROLE OF STABILIZATION OF MAMS AND MAM-ASSOCIATED PALMITOYLATED APP (MAM-PALAPP) IN ALZHEIMER'S DISEASE |
| UNIVERSITY OF RHODE ISLAND | KINGSTON, RI | $201,250 | 2024 | EFFECT OF APOE GENOTYPE IN A NOVEL RAT MODEL OF CEREBRAL AMYLOID ANGIOPATHY |
| UNIVERSITY OF VIRGINIA | CHARLOTTESVILLE, VA | $201,250 | 2024 | ELUCIDATING THE ROLE OF CLEC7A IN TAU-MEDIATED NEURODEGENERATIVE DISEASE |
| UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | SAN ANTONIO, TX | $201,250 | 2024 | IDENTIFICATION AND VALIDATION OF PLASMA-BASED LIPID BIOMARKERS FOR EARLY ALZHEIMER'S DISEASE IN THE UNIQUE, PRIMARILY HISPANIC, SOUTH TEXAS POPULATION |
